Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $7.00

GoodRx (NASDAQ:GDRX - Get Free Report) had its price target cut by equities research analysts at Wells Fargo & Company from $8.00 to $7.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price target suggests a potential upside of 52.01% from the company's current price.

Several other research firms have also recently issued reports on GDRX. KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Truist Financial cut their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Citigroup cut their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, GoodRx currently has an average rating of "Moderate Buy" and an average target price of $7.84.

GoodRx Stock Performance

GoodRx stock traded down $0.03 during mid-day trading on Tuesday, reaching $4.61. 77,038 shares of the company traded hands, compared to its average volume of 1,373,975. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm's fifty day moving average is $4.57 and its two-hundred day moving average is $4.87. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $9.26. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -153.50, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in GoodRx by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock worth $38,935,000 after purchasing an additional 460,753 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock valued at $9,264,000 after acquiring an additional 369,553 shares during the last quarter. Clearbridge Investments LLC purchased a new position in GoodRx during the 4th quarter valued at about $5,863,000. Connor Clark & Lunn Investment Management Ltd. raised its position in GoodRx by 38.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock worth $5,714,000 after acquiring an additional 342,781 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after purchasing an additional 89,032 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.